Thu, Sep 18, 2014, 10:40 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Cardica Inc. Message Board

biotechbeagle 28 posts  |  Last Activity: Sep 15, 2014 10:21 PM Member since: Feb 11, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    I think Broadfin has their act together

    by marketmayvin Sep 14, 2014 2:30 PM
    biotechbeagle biotechbeagle Sep 15, 2014 10:21 PM Flag

    If you were happy the day the stock went up to $1.80 on news of the FDA approval and quickly sold off hurting you as a shareholder (if you really are), then Broadfin is for you.

    We hope Broadfin’s stated commitment to Cardica is for the long-term, but we note that Broadfin has been both a buyer and seller of Cardica stock. Notably, Broadfin sold the vast majority of its holdings in Cardica, severely impacting Cardica’s stock price, shortly before Cardica’s last public offering and Broadfin then purchased its current position in April, 2014, at a lower price.

    Sentiment: Strong Buy

  • Reply to

    I think Broadfin has their act together

    by marketmayvin Sep 14, 2014 2:30 PM
    biotechbeagle biotechbeagle Sep 15, 2014 5:07 PM Flag

    Broadfin is high on FLML and PGNX. Not aware of their big wins. Does anyone know?
    Not sure what they bring to the table besides Money and Investors. They may have a buyer at what price $2-3? What strategic consulting are they going to provide cardica to help win over surgeons or hospitals? I'd like to see them expand portfolio and gain Japan before any sale discussions are ever considered.

  • Reply to

    Biotech and Mops, we still like Cardica ?

    by fjmardjetko Sep 10, 2014 12:33 PM
    biotechbeagle biotechbeagle Sep 11, 2014 7:48 AM Flag

    Big market, duopoly, patents expire in 16', smart money invested in CRDC, disruptive technology - small size, articulation, commercialization just begun with more approvals coming Japan, Exchange 30 short shaft, exchange 45, now well funded - yes! All this gives me confidence this will be a winner! Sometimes things just don't move as fast as investors like, but the intrinsic value is absolutely there.

    Sentiment: Strong Buy

  • Have to hand it to Zacks! They did call it. Feel sorry for those that lightened up at the peak of their frustration. Let's hope it continues followed by some good news.

  • Reply to

    IMGN pipeline updated on web site

    by bioimmunomabman Aug 28, 2014 8:58 AM
    biotechbeagle biotechbeagle Aug 31, 2014 9:44 AM Flag

    Carol must be reading our message board! They have updated the pipeline moving both sanofi drugs to phase II and Biotest to Phase II. This could be why Zacks states analyst targets have moved up.

  • These expiring warrants will make for an interesting month. If the warrants expire, cardica won't have to issue the warrant holder the $4 million of stock that would further dilute (already factored in cardicas valuation) or the warrant holder will be willing to buy them at $1.45 which makes no sense since they can buy shares on the open market at $1.12. What will make this interesting is a Japan approval this month, a microcutter 45 fda submission or any demand for the stock. Are there 4 million sellers willing to sell at $1.12? We are trading at this level with little liquidity. September should prove to be an interesting month with stock price movement larger than we seen of late. Could be why Broadfin has moved in a big way recently.

    Sentiment: Strong Buy

  • Reply to

    Attempt at breakout

    by mershaw2001 Aug 26, 2014 1:39 PM
    biotechbeagle biotechbeagle Aug 26, 2014 2:38 PM Flag

    Well one thing is clear, no one is buying on M& A speculation. The usual crowd of Biotechs rumored to be acquired are all up big today. Not us! But then again we are so quiet we've fallen off the radar.

  • biotechbeagle biotechbeagle Aug 26, 2014 1:13 PM Flag

    You are a complete moron! No more lunatic messages please!

  • biotechbeagle by biotechbeagle Aug 25, 2014 12:21 PM Flag

    Sanofi has this drug candidate in Phase 2, IMGN has it as Phase 1. It would be nice if they kept these up to date increasing the value of the pipeline. IMGN makes up almost 50% of Sanofi's Oncology Pipeline! Sanofi has bought REGN yet, so maybe their are happy with licensing deals. Interesting that they didn't comment on the Fast Track for IMGN853 and the advancement of their pipeline. They are conspicuous with their lack of investor communications!

  • Reply to

    Time to lighten up....

    by chinesehamsters Aug 22, 2014 12:29 PM
    biotechbeagle biotechbeagle Aug 25, 2014 9:25 AM Flag

    Bio, phase II is where the value creation and shareholder value begins. We have to get these wholly owned dosed right. I do believe that Sanofi (5 compounds, 1 phase II), Amgen (4 compounds) and Novartis are the likely targets. One has to look at big pharma's current oncology portfolio, type of cancer (ADC platform proven to work), patent expirations and annual sales. If IMGNs ADC can extent the patent life with a more effective and less toxic formula, the acquisition price for IMGN looks very reasonable.

  • Reply to

    Stock Performance Disappointing

    by themovingfinger214 Aug 17, 2014 7:52 PM
    biotechbeagle biotechbeagle Aug 18, 2014 12:19 PM Flag

    Not true, a major uptrend signal. The 50 day moving average has clearly crossed and sustained above the 200 moving average, aka the "Goldern Cross" which is a very bullish sign. Japan approval will push this over $1.40. Coming any day as it was filed last August. Wed Bush has a $4.00 target post the Q3 Earnings call

  • biotechbeagle by biotechbeagle Aug 14, 2014 6:47 AM Flag

    Wedbush stated they have a $4.00 target on crdc when they introduced Bernard's presentation. He did a great job. Really emphasized they IP and mentioned more parents are forthcoming.

  • Reply to

    Manipulators

    by bozedar1 Aug 11, 2014 10:29 AM
    biotechbeagle biotechbeagle Aug 11, 2014 3:12 PM Flag

    The early sell for $1.03 was clearly someone trolling to see if they could line up more sellers. Didn't happen! Century Medical will be a catalyst as they have a strong sales force with reach something cardiac doesn't have in the USA. Japan also is a big on miniaturization and a less-invasive procedures. Cardica may also surprise with an earlier than anticipated submission for the 30 exchange short shaft and 45 microcutters. Each of these catalysts will cause analyst to revise targets.

  • Reply to

    Lows since 2011, Junius and BOD must go!

    by bioimmunomabman Jul 25, 2014 11:19 AM
    biotechbeagle biotechbeagle Jul 25, 2014 4:46 PM Flag

    Maybe Roche helping drive down IMGN Stock to acquire on the cheap, then drive Kadcyla with 100% ownership. GSK screwed HGSI with their Lupus drug in early launch driving the price down only to pick them up on the cheap.

  • Reply to

    hedge fund increases stake

    by bozedar1 Jul 24, 2014 3:26 PM
    biotechbeagle biotechbeagle Jul 24, 2014 6:03 PM Flag

    This suggests possible BOD shake up with their new 10% of influence.

    "Broadfin Capital reports 9.98% stake in Cardica Broadfin Capital has recently engaged, and intend to continue to engage, in discussions with the company’s management and board of directors regarding the composition of the Board, generally, and means to enhance stockholder value."

    I'm sure Broadfin sees possible catalysts just ahead such as Japan Microcutter Approval, Microcutter 45 exchange submission and possible ISRG DaVinci Microcutter. R&D surely has made progress since that original licensing deal.

  • Reply to

    Perjeta

    by slumdawg2011 Jul 24, 2014 10:08 AM
    biotechbeagle biotechbeagle Jul 24, 2014 10:19 AM Flag

    Kadcyla is Herceptin cannibalization where Perjeta is an add to existing correct?

  • Reply to

    PUMA Phase 3 Success

    by biotechbeagle Jul 23, 2014 10:58 AM
    biotechbeagle biotechbeagle Jul 23, 2014 1:42 PM Flag

    Slumdawg thanks for the quick analysis and facts! Much appreciated. Thanks for being a poster on this board, too quiet around here!

  • biotechbeagle by biotechbeagle Jul 23, 2014 10:58 AM Flag

    How does PUMA Her2 Breast Cancer Likely approval impact Kadcyla?

  • Reply to

    revenue from ovarian orphan drug status from FDA?

    by my_daddie Jul 15, 2014 3:29 PM
    biotechbeagle biotechbeagle Jul 18, 2014 11:54 AM Flag

    Much to your chagrin stock grants were handed to sr leadership. Dan gets 210k, while lambert, Johnston and Morris get 100k. Directors like O'Leary get 80k all at $10.79

  • Reply to

    revenue from ovarian orphan drug status from FDA?

    by my_daddie Jul 15, 2014 3:29 PM
    biotechbeagle biotechbeagle Jul 17, 2014 5:29 PM Flag

    Bio, I feel your pain and are also frustrated. How much of it is simply the steep challenges in science and especially oncology? I would be disappointed with the management team if we didn't have 17 clinical trials going on, 1 approval and 4 wholly owned with the who's who of oncology, had no focus and wasted money. If it was that bad, wouldn't also invite activists like Icahn and Ackerman? I feel we've been beat down much like HGSI after their Lupus approval then acquired by GSK. Things are being overly hyped with a negative slant.

    I find it very strange they didn't post the Orphan Designation News.

    This was from a seeking alpha article:

    "A near term catalyst for an Immunogen stock price jump comes from the possibility of it being acquired. Recently, the company's executives filed an 8K form. The 8K form outlined the compensatory arrangement and departure process of officers in the event of a merger or consolidation. Immunogen may be acquired at any time this year given that it sits on $211 million in cash with no debt and that a widely expected FDA approval of T-DM1 is right around the corner."

CRDC
1.19-0.04(-3.25%)Sep 18 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Oracle Corporation
NYSEThu, Sep 18, 2014 4:04 PM EDT
Concur Technologies, Inc.
NasdaqGSThu, Sep 18, 2014 4:00 PM EDT
Rite Aid Corporation
NYSEThu, Sep 18, 2014 4:02 PM EDT